FierceBiotechOriginal article
{"a":[{"_":"J&J MedTech growth slows again in Q2 as Abiomed weighs on results","$":{"href":"/medtech/jj-medtech-sales-trajectory-continues-ease-q2-abiomed-drags-sales","hreflang":"en"}}]}
EarningsNegative
AI Analysis
Summary
Johnson & Johnson's MedTech division reported Q2 operational sales growth of 3.6% to $8.93 billion, with weaker Abiomed sales negatively impacting the segment's performance.
Financial Highlights
Revenue
$8.93 billion
Importance:3/10
Sentiment:
-0.30
earningsMedTechQ2 2026Abiomedoperational sales growth
Related Companies
Read the original article
Published by FierceBiotech on July 15, 2026 8:26 AM